Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo

Overexpression of the multidrug resistance (MDR)-related protein P-glycoprotein (PGP1), which actively extrudes chemotherapeutic agents from cells and significantly decreases the efficacy of chemotherapy, is viewed as a major obstacle in osteosarcoma chemotherapy. Anlotinib, a novel tyrosine kinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Gangyang, Cao, Lingling, Jiang, Yafei, Zhang, Tao, Wang, Hongsheng, Wang, Zhuoying, Xu, Jing, Mao, Min, Hua, Yingqi, Cai, Zhengdong, Ma, Xiaojun, Hu, Shuo, Zhou, Chenghao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801797/
https://www.ncbi.nlm.nih.gov/pubmed/35111065
http://dx.doi.org/10.3389/fphar.2021.798837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801797/
https://www.ncbi.nlm.nih.gov/pubmed/35111065
http://dx.doi.org/10.3389/fphar.2021.798837

Ejemplares similares